Paul Tudor Jones's ELVN Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 40,118 shares of Enliven Therapeutics, Inc. (ELVN) worth $2.04 M, representing 0.00% of the portfolio. First purchased in 2024-Q2, this short-term holding has been held for 8 quarters.
Based on 13F filings, Paul Tudor Jones has maintained this position in ELVN for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 40,118 shares. Largest reduction occurred in Q1 2026, reducing 29,673 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Enliven Therapeutics (ELVN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Enliven Therapeutics (ELVN) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +40,118 | New Buy | 40,118 | $50.75 |
| Q1 2026 | -29,673 | Sold Out | 0 | $0.00 |
| Q4 2025 | +13,370 | Add 82.01% | 29,673 | $15.40 |
| Q3 2025 | +16,303 | New Buy | 16,303 | $20.47 |
| Q2 2025 | -13,363 | Sold Out | 0 | $0.00 |
| Q1 2025 | +13,363 | New Buy | 13,363 | $19.68 |
| Q3 2024 | -24,221 | Sold Out | 0 | $0.00 |
| Q2 2024 | +24,221 | New Buy | 24,221 | $23.37 |
Paul Tudor Jones's Enliven Therapeutics Investment FAQs
Paul Tudor Jones first purchased Enliven Therapeutics, Inc. (ELVN) in Q2 2024, acquiring 24,221 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Enliven Therapeutics, Inc. (ELVN) for 8 quarters since Q2 2024.
Paul Tudor Jones's largest addition to Enliven Therapeutics, Inc. (ELVN) was in Q2 2026, adding 40,118 shares worth $2.04 M.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 40,118 shares of Enliven Therapeutics, Inc. (ELVN), valued at approximately $2.04 M.
As of the Q2 2026 filing, Enliven Therapeutics, Inc. (ELVN) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Enliven Therapeutics, Inc. (ELVN) was 40,118 shares, as reported at the end of Q2 2026.